Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Kura Oncology Inc | KURA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 19.00 | 08:31:50 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 19.00 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 7.41 - 24.17 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 19.00 | USD |
Kura Oncology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.45B | 76.14M | - | 0 | -152.63M | -2.00 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Kura Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KURA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 17.61 | 19.27 | 16.79 | 18.33 | 1,231,762 | 1.39 | 7.89% |
| 1 Month | 21.19 | 21.89 | 16.79 | 19.11 | 871,294 | -2.19 | -10.34% |
| 3 Months | 20.98 | 24.17 | 16.79 | 20.68 | 949,274 | -1.98 | -9.44% |
| 6 Months | 7.67 | 24.17 | 7.52 | 16.93 | 1,225,009 | 11.33 | 147.72% |
| 1 Year | 10.86 | 24.17 | 7.41 | 14.48 | 997,015 | 8.14 | 74.95% |
| 3 Years | 28.24 | 28.81 | 7.41 | 15.15 | 836,744 | -9.24 | -32.72% |
| 5 Years | 14.75 | 43.00 | 6.34 | 17.73 | 709,691 | 4.25 | 28.81% |
Kura Oncology Description
| Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. |
